Brind.
  1. A research firm released an update on Ensysce Biosciences, noting the company received a $5.3 million installment for a platform study conducted in collaboration with a CRO.

Ensysce Biosciences announced that on July 16, 2025, Rho, Inc. was selected as their clinical research partner.

1 report, 1 independent Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Ensysce Biosciences announced that on July 16, 2025, Rho, Inc. was selected as their clinical research partner.

Who's involved

What this event is mainly about
Ensysce BiosciencesDokumeds, SIA

Keep exploring

Part of

A research firm released an update on Ensysce Biosciences, noting the company received a $5.3 million installment for a platform study conducted in collaboration with a CRO. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • ACCESS NewswireEnsysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse ~ FDA Protocol Review Completed ~ ~ Rho, Inc. Selec